The novel anti-CTLA4 agents have already been approved or are under examination in the context of treatment of melanoma, non-small cell lung cancer, oesophageal squamous cell carcinoma and renal cell carcinoma [85,86,87,88]. Here, CTLA4 is linked to hereditary clear cell renal cell carcinoma.